Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 375)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 0
Gesamt: 389.977
Gesamt: 389.977
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
7,5200
USD
-3,84 %
-0,3000 USD
Letzter Kurs 01:00:00 NYSE
Neuigkeiten
02.05.24 · Accesswire  |
25.04.24 · wO Chartvergleich |
11.04.24 · Accesswire |
11.04.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 119,40 | +29,92 | |
| 6,5000 | +27,45 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8744 | -13,43 | |
| 4,1900 | -14,49 | |
| 1,4500 | -20,98 | |
| 11,290 | -42,81 | |
| 0,5001 | -87,59 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 54.421.447 von bernie55 am 27.02.17 16:52:40"Wer hoch stiegen will, muss es gegen den Wind tun".
(Chinesische Weisheit)
(Chinesische Weisheit)
Folgende Börsenweisheiten scheinen dann wohl absolut für ein Investment VALEANT zu sprechen :
"Es ist unmöglich, überdurchschnittliche Renditen zu erreichen, wenn man nicht anders handelt als die Mehrheit".
"Investiere in der Zeit des größten Pessimismus".
"Wer ein Papier für die Hälfte oder ein Viertel des Wertes kauft, geht weniger Risiko ein als jemand, der den vollen Wert bezahlt".
"Es ist unmöglich, überdurchschnittliche Renditen zu erreichen, wenn man nicht anders handelt als die Mehrheit".
"Investiere in der Zeit des größten Pessimismus".
"Wer ein Papier für die Hälfte oder ein Viertel des Wertes kauft, geht weniger Risiko ein als jemand, der den vollen Wert bezahlt".
Antwort auf Beitrag Nr.: 54.415.684 von X-Remi am 26.02.17 18:44:09viele instituielle ändern ihre Bestand an Valeant ständig
Hier dann mal einige " targets" von einigen Institutionellen. Wenn man bedenkt, dass die Aktie mal von > 250 $ kam und die durchschnittlichen Prognosen von den Instis ( siehe unten ) eintreffen sollten, dann könnten wir zufrieden sein - natürlich nur unter der Voraussetzung, dass die Jungs von VRX die aktuelle katastrophale Finanzsituation in den Griff bekommen....
TIME WILL TELL
THE VALEANT PHARMACEUTICALS INTERNATIONAL INC. (VRX) RATING REITERATE BY THE DEUTSCHE BANK AG
February 26, 2017 Susan G. Crespo
The Valeant Pharmaceuticals International Inc. (VRX) Rating Reiterate by the Deutsche Bank AG
Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reissued by equities research analysts at Deutsche Bank AG in a research note issued to investors on Wednesday. They currently have a $24.00 price objective on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s target price would suggest a potential upside of 69.61% from the company’s current price.
VRX has been the topic of a number of other reports. Wells Fargo & Co. reissued an “underperform” rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, October 18th.
JPMorgan Chase & Co. reissued a “neutral” rating on shares of Valeant Pharmaceuticals International in a report on Tuesday, October 25th. RBC Capital Markets reissued a “sector perform” rating and issued a $46.00 price objective on shares of Valeant Pharmaceuticals International in a report on Monday, September 26th.
Royal Bank Of Canada lowered their target price on Valeant Pharmaceuticals International from $36.00 to $35.00 and set a “sector perform” rating on the stock in a research note on Wednesday, October 12th.
Finally, Morgan Stanley restated an “overweight” rating and issued a $42.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 2nd.
Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $34.80.
http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int…" target="_blank" rel="nofollow ugc noopener">http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int…
Zitat von X-Remi: http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int…
Hier dann mal einige " targets" von einigen Institutionellen. Wenn man bedenkt, dass die Aktie mal von > 250 $ kam und die durchschnittlichen Prognosen von den Instis ( siehe unten ) eintreffen sollten, dann könnten wir zufrieden sein - natürlich nur unter der Voraussetzung, dass die Jungs von VRX die aktuelle katastrophale Finanzsituation in den Griff bekommen....
TIME WILL TELL
THE VALEANT PHARMACEUTICALS INTERNATIONAL INC. (VRX) RATING REITERATE BY THE DEUTSCHE BANK AG
February 26, 2017 Susan G. Crespo
The Valeant Pharmaceuticals International Inc. (VRX) Rating Reiterate by the Deutsche Bank AG
Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reissued by equities research analysts at Deutsche Bank AG in a research note issued to investors on Wednesday. They currently have a $24.00 price objective on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s target price would suggest a potential upside of 69.61% from the company’s current price.
VRX has been the topic of a number of other reports. Wells Fargo & Co. reissued an “underperform” rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, October 18th.
JPMorgan Chase & Co. reissued a “neutral” rating on shares of Valeant Pharmaceuticals International in a report on Tuesday, October 25th. RBC Capital Markets reissued a “sector perform” rating and issued a $46.00 price objective on shares of Valeant Pharmaceuticals International in a report on Monday, September 26th.
Royal Bank Of Canada lowered their target price on Valeant Pharmaceuticals International from $36.00 to $35.00 and set a “sector perform” rating on the stock in a research note on Wednesday, October 12th.
Finally, Morgan Stanley restated an “overweight” rating and issued a $42.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 2nd.
Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $34.80.
http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int…" target="_blank" rel="nofollow ugc noopener">http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int…
und wieder ein neuer Antrag für ein neues Medi von Valeant...die Zusage ist 100% sicher,, bei der ersten Vorlage wurde der Antrag nur wegen technischer herstellungsgründe zurückgewiesen..
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=2…
viele instituielle ändern ihre Bestand an Valeant ständig
http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int… Trading Spotlight
Erwartungen
www.forbes.com/sites/adamsarhan/2017/02/26/q4-2016-earnings-…http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int…" target="_blank" rel="nofollow ugc noopener">
http://dailyquint.com/2017-02-26-valeant-pharmaceuticals-int…
Experimental: IDP-121 Lotion
IDP-121 Lotion
Drug: IDP-121 Lotion
Lotion
Other Name: Lotion
Active Comparator: IDP-121 Vehicle Lotion
IDP-121 Vehicle Lotion Vehicle
Drug: IDP-121 Vehicle Lotion
Vehicle
Other Name: Vehicle
Detailed Description:
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Eligibility
Ages Eligible for Study: 9 Years and older (Child, Adult, Senior)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Key Inclusion Criteria:
Male or female at least 9 years of age and older
Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit)
Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment at the screening and baseline visit
Key Exclusion Criteria:
Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study
Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis
Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive
Subjects with a facial beard or mustache that could interfere with the study assessments
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02932306
Contacts
Contact: Tim Theisen 201-587-0500 ext 5202 ttheisen@tklresearch.com
Show 39 Study Locations
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
Investigators
Study Chair: Tim Theisen TKL Research, Inc.
More Information
Responsible Party: Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier: NCT02932306 History of Changes
Other Study ID Numbers: V01-121A-301
Study First Received: October 11, 2016
Last Updated: November 11, 2016
Individual Participant Data
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
ClinicalTrials.gov processed this record on February 24, 2017
IDP-121 Lotion
Drug: IDP-121 Lotion
Lotion
Other Name: Lotion
Active Comparator: IDP-121 Vehicle Lotion
IDP-121 Vehicle Lotion Vehicle
Drug: IDP-121 Vehicle Lotion
Vehicle
Other Name: Vehicle
Detailed Description:
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Eligibility
Ages Eligible for Study: 9 Years and older (Child, Adult, Senior)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Key Inclusion Criteria:
Male or female at least 9 years of age and older
Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit)
Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment at the screening and baseline visit
Key Exclusion Criteria:
Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study
Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis
Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive
Subjects with a facial beard or mustache that could interfere with the study assessments
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02932306
Contacts
Contact: Tim Theisen 201-587-0500 ext 5202 ttheisen@tklresearch.com
Show 39 Study Locations
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
Investigators
Study Chair: Tim Theisen TKL Research, Inc.
More Information
Responsible Party: Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier: NCT02932306 History of Changes
Other Study ID Numbers: V01-121A-301
Study First Received: October 11, 2016
Last Updated: November 11, 2016
Individual Participant Data
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
ClinicalTrials.gov processed this record on February 24, 2017
auch dieses produkt
Drug: IDP-122 Lotion
Drug: IDP-122 Vehicle Lotion
https://clinicaltrials.gov/ct2/show/NCT02514577
Drug: IDP-122 Lotion
Drug: IDP-122 Vehicle Lotion
https://clinicaltrials.gov/ct2/show/NCT02514577
ich würde nach der Liste sagen ,dass IDP-124 ist sehr versprechend und ein über 20millarden Markt warten auf dieses Produkt...nämlich die atrophische Dematitis hat/bekommt jede 3 person im verlauf seines Lebens und kann von alleine veschwinden oder weniger ausgeprägt bleiben wie z.B neurodemitis bei Kinder
https://clinicaltrials.gov/ct2/show/NCT03002571
https://clinicaltrials.gov/ct2/show/NCT03002571
ich glaube, das ist das wichtigste Kapital von Valeant dieses Jahr....
http://www.valeant.com/operational-expertise/valeant-united-…
http://www.valeant.com/operational-expertise/valeant-united-…
Durchsuchen
25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt |
04.03.24 · wO Chartvergleich · Myriad Genetics |